GHK-Cu Research Guide: Copper Tripeptide & ECM Remodeling

What Is GHK-Cu?

GHK-Cu is the copper(II) complex of the human tripeptide GHK — glycyl-L-histidyl-L-lysine (Gly-His-Lys). The free peptide GHK has the molecular formula C₁₄H₂₄N₆O₄ and a molecular weight of about 340.4 g/mol; the metal complex carries a chelated copper(II) ion (complex formula approximately C₁₄H₂₂CuN₆O₄). GHK was isolated from human plasma/albumin fractions by Loren Pickart, who first reported the activity in 1973 and identified the sequence as Gly-His-Lys in 1977. It occurs naturally in human plasma, saliva, and urine, and its plasma levels decline with age.

The defining feature of GHK is a very high affinity for copper(II): the published stability constant for GHK-Cu is log K ≈ 16.4, comparable to copper's transport site on serum albumin — which is what lets GHK act as a physiological copper carrier. In solution the bound copper(II) gives reconstituted GHK-Cu its characteristic blue / blue-green color (the d-d absorption of the Cu(II) coordination complex). Within this site's catalog, GHK-Cu is also the active copper peptide in the GLOW and KLOW research blends.

Mechanism of Action: What the Research Shows

The literature describes two intertwined modes of action for GHK-Cu, and they are best kept distinct in any research design.

Copper Delivery

GHK binds Cu(II) with high affinity (log K ≈ 16.4, near albumin's copper transport site) and is proposed to shuttle copper into cells, where copper is a cofactor for enzymes including lysyl oxidase (collagen/elastin cross-linking) and superoxide dismutase (antioxidant defense). The strongest direct evidence that this copper-delivery component is real comes from the MMP-2 study (Siméon et al., Life Sciences, 2000): the matrix-metalloproteinase-2 induction in fibroblasts was reproduced by copper ions but not by the GHK peptide alone — underscoring a copper-dependent signaling component.

Broad Gene-Expression Modulation

Analyses of the Broad Institute Connectivity Map (cMap) data, reported by the Pickart group, indicate that GHK alters expression of a large fraction of human genes (cited at roughly 31–32% of analyzed genes at a ≥50%-change threshold), upregulating tissue-repair, antioxidant, and DNA-repair programs while downregulating inflammatory and tissue-destructive ones. These gene-count figures are method- and dataset-dependent — they vary with the database version and change-threshold used — so they should be read as approximate and attributed to the Pickart-lab cMap analyses rather than as a fixed, independently established fact.

At the Extracellular-Matrix Level

At the ECM level GHK-Cu stimulates synthesis of collagen (types I and III), elastin, glycosaminoglycans (dermatan/chondroitin sulfate), and the small proteoglycan decorin, and it modulates the MMP/TIMP balance. Together these describe extracellular-matrix remodeling rather than mere accumulation. Notably, the reported collagen-synthesis effects appear at strikingly low concentrations (picomolar onset, nanomolar peak). All of this is in-vitro and animal-model data.

What the Research Literature Reports

The GHK-Cu evidence base is mechanistically rich but predominantly preclinical: peer-reviewed in-vitro fibroblast studies, rodent-wound work, and bioinformatic analyses, with limited rigorous human clinical-trial evidence for systemic claims. The findings below are reported for context on what the published literature has observed; none of it is presented as a use indication for research-grade material.

Collagen Synthesis in Fibroblasts (the foundational finding)

The foundational in-vitro result (Maquart et al., FEBS Letters, 1988) reported that GHK-Cu stimulated collagen synthesis in cultured fibroblasts at very low concentrations — stimulation began between 10⁻¹² and 10⁻¹¹ M and peaked at 10⁻⁹ M — and that this occurred independently of any change in cell number, indicating a signaling effect rather than simple proliferation.

ECM Proteoglycans and Glycosaminoglycans

Work on rat experimental wounds and dermal fibroblast cultures (Siméon et al., Journal of Investigative Dermatology, 2000) reported that GHK-Cu increased type I collagen, glycosaminoglycans (dermatan sulfate, chondroitin sulfate), and stimulated decorin expression, while biglycan was unchanged — evidence for selective ECM and proteoglycan remodeling rather than indiscriminate matrix deposition.

MMP/TIMP Balance

A separate fibroblast study (Siméon et al., Life Sciences, 2000) reported that GHK-Cu raised matrix-metalloproteinase-2 (MMP-2) expression and mRNA and increased TIMP-1/TIMP-2 secretion. As noted in the mechanism section, the MMP-2 effect was reproduced by copper ions but not by the GHK peptide alone — the clearest single piece of evidence for the copper-dependent component of ECM-turnover signaling.

Genome-Wide Expression and Review Synthesis

Several reviews from the Pickart group synthesize the broader picture. Pickart et al., Brain Sciences, 2017 analyzed cMap data — in which GHK was ranked the most active of 1,309 tested bioactive molecules in 2010 — and reported modulation of a large share of analyzed genes (~31–32% at a ≥50%-change threshold). Pickart & Margolina, International Journal of Molecular Sciences, 2018 is a comprehensive review of the proposed mechanism (copper delivery; collagen/elastin/glycosaminoglycan synthesis; antioxidant and DNA-repair gene modulation), and the earlier Pickart, Journal of Biomaterials Science, Polymer Edition, 2008 framed GHK / GHK-Cu as a tissue-remodeling signal with a copper(II) affinity similar to albumin's transport site. A related review, Pickart et al., BioMed Research International, 2014, discusses GHK reversing age-shifted gene-expression patterns via cMap signature matching. It is worth noting that this genome-wide narrative is concentrated in one research lineage and is partly interpretive — cMap is a signature-matching bioinformatic tool, not direct in-vivo proof.

Reconstitution & Handling for Research

GHK-Cu ships as a lyophilized (freeze-dried) powder and is reconstituted into solution before use in research preparations. A few handling characteristics are specific to this copper complex and worth flagging:

• Use a water-based diluent, not saline. GHK-Cu is reconstituted with sterile water or bacteriostatic water (sterile water with ~0.9% benzyl alcohol; bacteriostatic is preferred when a solution will be drawn from over days). Avoid plain saline (0.9% NaCl): chloride can compete for and displace the bound copper, so water-based diluents are the standard for keeping the Cu(II)–peptide complex intact.
• Mix gently — do not shake. Add diluent down the vial wall and swirl until fully dissolved, rather than agitating vigorously.
• The blue color is expected. A correctly reconstituted GHK-Cu solution shows a characteristic blue / blue-green tint — this is the spectroscopic signature of the chelated copper(II) ion, not contamination. Note this is a property of the Cu(II) complex, not a purity or COA guarantee.

Store lyophilized powder cold and protected from light; refrigerate (2–8 °C) reconstituted solution and do not freeze it, since freeze–thaw cycling can damage the peptide. These are general peptide-handling practices grounded in copper(II) coordination chemistry, not therapeutic instruction. Reported refrigerated stability windows (for example, the ~28–30 days sometimes cited) come from vendor and secondary sources and vary by source and formulation — confirm exact stability windows against the supplier's certificate of analysis.

GHK-Cu vs AHK-Cu

GHK-Cu is frequently searched alongside AHK-Cu, and the two are genuinely related — both are copper tripeptide complexes — but they are not interchangeable.

AHK-Cu is alanyl-L-histidyl-L-lysine–Cu (Ala-His-Lys), differing from GHK by a single N-terminal residue (alanine in place of glycine), which gives it a slightly higher molecular weight (~354 Da peptide versus ~340 Da for GHK). The His-Lys motif that coordinates copper is conserved between them, so both deliver copper and engage ECM/fibroblast pathways.

The practical distinction in the literature is the depth and focus of the research:

• GHK-Cu — the far larger, decades-deep evidence base centered on skin/ECM remodeling, collagen synthesis, wound healing, and genome-wide expression (the Pickart-lab body of work). GHK also occurs naturally in human plasma.
• AHK-Cu — a newer, more narrowly studied synthetic analog, most often examined in hair-follicle / dermal-papilla-cell contexts (for example, ex-vivo follicle and dermal-papilla proliferation models). Its evidence base is considerably thinner.

A caveat worth keeping in any comparative design: head-to-head GHK-Cu versus AHK-Cu data are limited, and the AHK literature is much smaller — treat the hair-follicle distinction as suggestive, not as established equivalence or superiority. (Within this site's catalog, GHK-Cu is the copper peptide used in the GLOW and KLOW research blends, mentioned here as catalog context, not as a combined-efficacy claim.) For broader pairing context across compounds, see our guide to research peptide stacks.

Evaluating Research-Grade GHK-Cu Supply

For reproducible work on copper-peptide and ECM pathways, the supply chain matters as much as the compound. When sourcing GHK-Cu for research, look for:

1. A Batch-Specific Third-Party COA

A legitimate vendor provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a copper tripeptide, the COA should report:

• HPLC purity — the analytical purity of the peptide for the specific lot.
• Mass-spec confirmation — verifying the measured mass matches the expected GHK peptide (~340 Da) plus the copper complex, which is how you confirm you actually received the intended tripeptide and not a mislabeled or truncated sequence.
• Batch / lot number and a recent test date linking the COA to your specific vial.

Elytra Labs publishes batch-specific third-party COAs for every research peptide we ship. Browse our current COA library → and see our guide to reading a peptide COA for how to interpret the chromatogram and mass-spec data.

2. Lyophilized Form and Cold-Chain Discipline

GHK-Cu should arrive as a lyophilized powder. Keep it cold and sealed until reconstitution, and reconstitute with a clean water-based diluent rather than saline. Because the copper complex is light-sensitive and the bound copper can be displaced by chloride, a vendor that ships it properly and documents handling guidance is doing real quality control, not just shipping powder.

Frequently Asked Research Questions

What is GHK-Cu?

GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine (Gly-His-Lys). The peptide weighs about 340 Da (C₁₄H₂₄N₆O₄) and binds a chelated copper(II) ion. It was discovered by Loren Pickart — activity reported in 1973, sequence identified in 1977 — and occurs naturally in human plasma, declining with age.

Why is reconstituted GHK-Cu blue?

The blue / blue-green color is the spectroscopic signature of the bound copper(II) ion (its d-d absorption) and is expected, not a sign of contamination. Note that color is a property of the Cu(II) complex itself, not a substitute for a purity or COA verification.

Why is saline not recommended as a diluent?

GHK binds copper(II) with very high affinity (stability constant log K ≈ 16.4), but chloride from saline (0.9% NaCl) can compete for and displace the chelated copper. Water-based diluents — sterile or bacteriostatic water — are the standard because they keep the Cu(II)–peptide complex intact.

How does GHK-Cu differ from AHK-Cu?

AHK-Cu (alanyl-histidyl-lysine–Cu, ~354 Da) is a closely related copper tripeptide differing from GHK by a single residue. GHK-Cu has a much larger, decades-deep evidence base in skin/ECM remodeling and collagen synthesis; AHK-Cu is newer and studied mainly in hair-follicle/dermal-papilla contexts, with a thinner literature. Head-to-head data between the two are limited.

What does "research-grade" mean?

It indicates the peptide is intended for laboratory in vitro and animal-model investigation, synthesized in an appropriate facility, and accompanied by analytical documentation (purity, mass spec, batch records). It is not pharmaceutical- or human-grade and is not approved for human or veterinary therapeutic use. All cited GHK-Cu data are in-vitro or animal-model, with no human therapeutic claims.